



Original article

Neutrophil, lymphocyte and platelet ratio as a predictor of mortality in septic-acute kidney injury patients

Joana Gameiro^{a,*}, José Agapito Fonseca^a, Sofia Jorge^a, João Gouveia^b, José António Lopes^a

^a Division of Nephrology and Renal Transplantation, Department of Medicine, Centro Hospitalar Lisboa Norte, EPE, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal

^b Division of Intensive Medicine, Department of Medicine, Centro Hospitalar Lisboa Norte, EPE, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal

ARTICLE INFO

Article history:

Received 27 July 2019

Accepted 10 November 2019

Available online 13 January 2020

Keywords:

Acute kidney injury

Sepsis

Mortality

Prognosis

Epidemiology

ABSTRACT

Background: AKI is frequent in critically ill patients, in whom the leading cause of AKI is sepsis. The role of intrarenal and systemic inflammation appears to be significant in the pathophysiology of septic-AKI. The neutrophils to lymphocytes and platelets (N/LP) ratio is an indirect marker of inflammation. The aim of this study was to evaluate the prognostic ability of N/LP ratio at admission in septic-AKI patients admitted to an intensive care unit (ICU).

Methods: This is a retrospective analysis of 399 septic-AKI patients admitted to the Division of Intensive Medicine of the Centro Hospitalar Universitário Lisboa Norte between January 2008 and December 2014. The Kidney Disease Improving Global Outcomes (KDIGO) classification was used to define AKI. N/LP ratio was calculated as: (Neutrophil count × 100)/(Lymphocyte count × Platelet count).

Results: Fifty-two percent of patients were KDIGO stage 3, 25.8% KDIGO stage 2 and 22.3% KDIGO stage 1. A higher N/LP ratio was an independent predictor of increased risk of in-hospital mortality in septic-AKI patients regardless of KDIGO stage (31.59 ± 126.8 vs 13.66 ± 22.64 , $p=0.028$; unadjusted OR 1.01 (95% CI 1.00–1.02), $p=0.027$; adjusted OR 1.01 (95% CI 1.00–1.02), $p=0.015$). The AUC for mortality prediction in septic-AKI was of 0.565 (95% CI 0.515–0.615), $p=0.034$).

Conclusions: The N/LP ratio at ICU admission was independently associated with in-hospital mortality in septic-AKI patients.

© 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: joana.estrelagameiro@gmail.com (J. Gameiro).

<https://doi.org/10.1016/j.nefro.2019.11.006>

0211-6995/© 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Relación entre neutrófilos, linfocitos y plaquetas como factor pronóstico de mortalidad en pacientes con lesión renal aguda por sepsis

R E S U M E N

Palabras clave:

Lesión renal aguda
Sepsis
Mortalidad
Pronóstico
Epidemiología

Antecedentes: La LRA es frecuente en pacientes críticos, en quienes la causa principal de LRA es la sepsis. El papel de la inflamación intrarrenal y sistémica parece ser significativo en la fisiopatología de la LRA por sepsis. La relación entre neutrófilos y linfocitos y plaquetas (N/LP) es un marcador indirecto de inflamación. El objetivo de este estudio fue evaluar la capacidad pronóstica de N/LP en el momento del ingreso en pacientes con LRA por sepsis ingresados en una unidad de cuidados intensivos.

Métodos: Se trata de un análisis retrospectivo de 399 pacientes con LRA por sepsis ingresados en la Unidad de Medicina Intensiva del Centro Hospitalario Universitario Lisboa Norte, entre enero de 2008 y diciembre de 2014. Se usó la clasificación del *Kidney Disease Improving Global Outcomes* (KDIGO) para definir la LRA. La relación N/LP se calculó como: (recuento de neutrófilos \times 100)/(recuento de linfocitos \times recuento de plaquetas).

Resultados: El 52% de los pacientes presentaba KDIGO estadio 3, el 25,8% KDIGO estadio 2 y el 22,3% KDIGO estadio 1. Un valor más elevado de N/LP fue un factor pronóstico independiente de mayor riesgo de mortalidad intrahospitalaria en pacientes con LRA por sepsis, independientemente del estadio KDIGO (31,59 \pm 126,8 frente a 13,66 \pm 22,64, $p=0,028$); OR sin ajustar 1,01 (IC del 95%: 1,00-1,02, $p=0,027$), OR ajustada 1,01 (IC del 95%: 1,00-1,02, $p=0,015$). El AUC para la predicción de mortalidad en la LRA por sepsis fue de 0,565 (IC del 95%: 0,515-0,615, $p=0,034$).

Conclusiones: La relación N/LP en el momento del ingreso en la unidad de cuidados intensivos se asoció de forma independiente con la mortalidad intrahospitalaria en pacientes con LRA por sepsis.

© 2019 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Background

Acute kidney injury (AKI) is characterized by a rapid decrease in renal function.¹ AKI is frequent in hospitalized patients and its incidence is higher in critically ill patients, in whom the leading cause of AKI is sepsis, substantiated by multiple cohorts.²⁻⁴ Sepsis is the systemic inflammatory response to an infectious insult, which often results in multiple organ dysfunction.^{5,6}

Septic-AKI patients have distinct characteristics than non-septic AKI, that is higher severity scores at admission, more non-renal organ failure and requirement of vasopressors and mechanical ventilation.^{3,7}

AKI has been associated with longer hospital stays, in-hospital mortality, cardiovascular events, progression to chronic kidney disease and long-term mortality.⁸⁻¹⁰ Septic-AKI also has distinct prognostic implications than non-septic AKI, namely higher short-term mortality rate, prolonged length of hospital stays and higher probability of renal function recovery at hospital discharge.^{3,7} Therefore, it is vital to detect predictors of AKI and mortality to timely prevent, diagnose and treat this complication.

Recent research has led to improvement in the understanding of the pathophysiology of septic-AKI, which is a complex interaction of hemodynamic, microcirculatory, inflammatory, and immune mechanisms.¹¹⁻¹⁴ Indeed, the role of intrarenal and systemic inflammation appears to be significant in the

pathophysiology of septic-AKI and in the associated multi-organ dysfunction.¹⁵⁻¹⁷

The neutrophil to lymphocyte ratio (N/L ratio) and neutrophil to lymphocytes and platelets ratio (N/LP ratio) have been associated with AKI in the emergency setting, sepsis, contrast induced-AKI, cardiovascular surgery and abdominal surgery.¹⁸⁻²³ These are easily calculated, effective and low-cost markers of systemic inflammation which might be promising in AKI patients.

The prognostic ability of the neutrophils to lymphocytes and platelets ratio (N/LP ratio) has not previously been evaluated in septic-AKI. The aim of this study was to evaluate the prognostic ability of N/LP ratio at admission in septic-AKI patients admitted to an intensive care unit (ICU). For this purpose, we cross-examined data from a retrospective study of critically ill patients admitted with sepsis to the ICU in which the initial goal was to compare the diagnostic sensitivity and prognostic ability of the standard classifications for AKI.²⁴

Materials and methods

This is a single center retrospective analysis of septic-AKI patients admitted to the Division of Intensive Medicine of the Centro Hospitalar Universitário Lisboa Norte (CHULN) between January 2008 and December 2014. CHULN is an academic and referral center located in Lisbon, Portugal. This study was approved by the Ethical Committee in agreement

with institutional guidelines. Due to the retrospective and non-interventional nature of the study, informed consent was waived by the Ethical Committee.

Participants

Eligible patients were selected as adult patients (≥ 18 years of age) with a diagnosis of sepsis at admission to the Division of Intensive Medicine which developed AKI within the first week of ICU hospitalization.

Exclusion criteria comprised (a) CKD patients on renal replacement therapy, (b) patients who underwent renal replacement therapy one week prior to admission to the ICU and (c) patients who were discharged or died less than two days after ICU admission.

Variables and outcomes

Patient variables were collected from individual clinical records. The protocol for all patients in this ICU includes daily determination of SCr and hourly UO.

The following variables were analyzed: patient demographic characteristics (age, gender, ethnicity, body weight and height); comorbidities [diabetes mellitus, hypertension, chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD), cirrhosis and/or malignancy]; main diagnosis on admission (medical vs surgical nature); source of infection; laboratory values at admission (serum hemoglobin, neutrophil, lymphocyte count and platelet count, serum albumin, SCr, arterial blood gas and pH analysis); disease severity according to the Simplified Acute Physiologic Score (SAPS) II²⁵ as determined by the worst variables documented throughout the first 24 h of ICU admission; fluid balance during ICU admission; mechanical ventilation, vasopressor use and requirement for renal replacement therapy.

The outcomes measured were length of stay and in-hospital mortality.

Definitions

The Kidney Disease Improving Global Outcomes (KDIGO) classification according to both serum creatinine (SCr) and urine output (UO) criteria was used to define AKI (Table 1).²⁶ Pre-admission SCr (SCr within the previous three months) was considered as baseline value. When unavailable, baseline SCr was estimated from the MDRD equation,²⁶ accepting the lower limit of a normal baseline GFR of 75 ml/min/1.73 m².

Table 1 – Kidney Disease Improving Global Outcomes (KDIGO) classification.

Stage	SCr/GFR	UO
1	\uparrow SCr $\geq 26.5 \mu\text{mol/l}$ ($\geq 0.3 \text{ mg/dl}$) or \uparrow SCr $\geq 150\text{--}200\%$ ($1.5\text{--}1.9\times$)	$<0.5 \text{ ml/kg/h}$ ($>6 \text{ h}$)
2	\uparrow SCr $> 200\text{--}300\%$ ($>2\text{--}2.9\times$)	$<0.5 \text{ ml/kg/h}$ ($>12 \text{ h}$)
3	\uparrow SCr $> 300\%$ ($\geq 3\times$) or \uparrow SCr to $\geq 353.6 \mu\text{mol/l}$ ($\geq 4 \text{ mg/dl}$) or initiation of renal replacement therapy	$<0.3 \text{ ml/kg/h}$ (24 h) or anuria (12 h)

Sepsis was diagnosed according to the third international consensus definitions as an acute change in total Sequential Organ Failure Assessment (SOFA) score ≥ 2 points consequent to the infection.²⁷ Diabetes mellitus was diagnosed according to the American Diabetes Association criteria²⁸ and hypertension was diagnosed according to the seventh report of the Joint National Committee.²⁹ COPD comprised emphysema and chronic bronchitis and CVD was considered as present whenever a history of cerebrovascular disease, chronic heart failure of any cause, cardiac ischemic disease and/or peripheral arterial disease was documented, also, a previous diagnosis on clinical records was considered sufficient for the confirmation of these diagnosis.

N/LP ratio at admission was calculated as: (Neutrophil count $\times 100$)/(Lymphocyte count \times Platelet count).

Statistical methods

Categorical variables were described as the total number and percentage for each category, whereas continuous variables were described as the mean \pm standard deviation. Normally distributed continuous variables were compared with the Student's t-test, non-normally distributed continuous variables were compared with the Mann-Whitney U test and categorical variables were compared with the chi-square test.

We performed univariate analysis in all variables to determine statistically significant factors that may have contributed to in-hospital mortality. Only variables with a significant statistical difference were included in the multivariate analysis using the Cox logistic regression method.

The discriminatory ability for N/LP ratio to predict mortality in septic-AKI patients was determined using the receiver operating characteristic (ROC) curve. A cut-off value was defined as that with the highest validity.

Data were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical significance was defined as a *p*-value < 0.05 . Statistical analysis was performed with the statistical software package SPSS for windows (version 21.0).

Results

We identified 722 septic patients. Of these, 323 were excluded as followed: 122 had stage 5 CKD on renal replacement therapy, 144 had been hospitalized for less than 48 h and 57 patients did not develop AKI during ICU stay. No patients required renal replacement therapy in the week preceding ICU admission (Fig. 1).

A final cohort of 399 patients was studied. Demographic variables, clinical and laboratory characteristics are described in Table 2.

In this cohort of septic-AKI patients, mean age was 64.1 ± 15.9 years, the majority were Caucasian (95%), males (57.4%) and the main diagnosis at ICU admission was medical in nature (55.6%). Forty-five percent of patients were hypertensive, 22.1% diabetic and 24.1% had malignancy. Baseline SCr was $1.27 \pm 0.6 \text{ mg/dl}$. The infection source was abdominal in 42.1%, respiratory in 30.6% and urinary in 10.8% of patients. At ICU admission mean SAPS II value was 50.4 ± 17.3 , SCr was $2.44 \pm 1.6 \text{ mg/dl}$, hemoglobin was 10.5 ± 2.0 , serum




Fig. 1 – Flow-chart of patient selection.

Table 2 – Patients' baseline characteristics.

Characteristic	Value
Age (year)	64.1 ± 15.9
Gender (male) – n (%)	229 (57.4)
Race (Caucasian) – n (%)	379 (95)
Obese (IMC ≥ 30) – n (%)	116 (29.1)
Co-morbidities – n (%)	
Hypertension	182 (45.6)
Diabetes	88 (22.1)
CVD	31 (7.8)
COPD	33 (8.3)
Cirrhosis	17 (4.3)
Neoplasia	96 (24.1)
Medical admission – n (%)	222 (55.6)
Infection source – n (%)	
Abdominal	168 (42.1)
Respiratory	122 (30.6)
Kidney	43 (10.8)
Skin	14 (3.5)
Others	20 (5.0)
Unknown	14 (3.5)
SAPS II	50.4 ± 17.3
Baseline SCr (mg/dl)	1.27 ± 0.6
Admission SCr (mg/dl)	2.44 ± 1.6
Hemoglobin (g/dl)	10.5 ± 2.0
Serum albumin (g/dl)	1.89 ± 0.6
Acidemia (pH < 7.5) – n (%)	143 (35.8)
NLP ratio	20.1 ± 78.4
Mechanical ventilation – n (%)	309 (77.4)
Vasopressors – n (%)	290 (72.7)
Fluid balance (l)	4.6 ± 5.4
RRT – n (%)	108 (27.1)
LOS in hospital (days)	36.7 ± 38.6
LOS in ICU (days)	10.0 ± 10.0
KDIGO stage 1 – n (%)	89 (22.3)
KDIGO stage 2 – n (%)	103 (25.8)
KDIGO stage 3 – n (%)	207 (51.9)
In-hospital mortality – n (%)	143 (35.8)

albumin was 1.89 ± 0.6 mg/dl and N/LP ratio was 20.1 ± 78.4 . Acidemia was present in 35.8% of patients at admission. The majority of patients were classified as KDIGO stage 3 (51.9%), 25.8% KDIGO stage 2 and 22.3% as KDIGO stage 1. The N/LP

ratio was progressively higher with the KDIGO stages but the differences were not statistically significant (KDIGO stage 1 – 13.7 ± 22.1 , KDIGO stage 2 – 18.5 ± 31.7 , KDIGO stage 3 – 23.6 ± 105.5 , $p = 0.591$). During ICU admission, 77.4% patients required mechanical ventilation, 72.7% required vasopressors, 27.1% required renal replacement therapy (RRT), and required mean fluid balance of 4.6 ± 5.4 l.

These patients had a length of stay in ICU of 10.0 ± 10.0 days and in hospital of 36.7 ± 38.6 days. The in-hospital mortality in this cohort of septic-AKI patients was 35.8% (KDIGO stage 1 – 13.3%, KDIGO stage 2 – 16.8%, KDIGO stage 3 – 69.9%, $p < 0.001$). Overall, patient survival was 64.2%.

Septic-AKI patients who died within the hospital admission were older (66.6 ± 15.9 vs 62.6 ± 15.7 , $p = 0.016$), had a higher incidence of malignancy (32.2% vs 19.5%, $p = 0.005$) and had fewer urinary tract infections (5.6% vs 13.7%, $p = 0.013$). At ICU admission, higher SAPS II (58.1 ± 17.7 vs 46.1 ± 15.6 , $p < 0.001$), lower hemoglobin level (9.9 ± 2.0 vs 10.8 ± 1.9 , $p < 0.001$) and lower serum albumin (1.78 ± 0.6 vs 1.94 ± 0.56 , $p = 0.010$) correlated with mortality. The N/LP ratio at admission was associated with in-hospital mortality in septic-AKI patients (31.59 ± 126.8 vs 13.66 ± 22.64 , $p = 0.028$). Need for mechanical ventilation (88.8% vs 71.1%, $p < 0.001$), vasopressors (81.8% vs 67.6%, $p = 0.002$), higher fluid balance (6.87 ± 5.99 vs 3.38 ± 4.6 , $p < 0.001$) and RRT (45.5% vs 16.8%, $p < 0.001$) also correlated with mortality (Table 3).

An adjusted multivariate analysis to demographic, clinical, ICU admission variables and during ICU stay factors was conducted, in which a higher N/LP ratio remained as an independent predictor of increased risk of in-hospital mortality in septic-AKI patients (31.59 ± 126.8 vs 13.66 ± 22.64 , $p = 0.028$; unadjusted OR 1.01 (95% CI 1.00–1.02), $p = 0.027$; adjusted OR 1.01 (95% CI 1.00–1.02), $p = 0.015$). After a sensitive analysis, a higher N/LP ratio was still associated with in-hospital mortality regardless of KDIGO stage (adjusted OR 1.01 (95% CI 1.00–1.02), $p = 0.030$) (Table 4).

Older age ($p = 0.004$), higher SAPS II ($p = 0.001$), lower hemoglobin ($p = 0.001$), higher fluid balance ($p < 0.001$) and need for RRT ($p < 0.001$) were also associated with mortality in the multivariate analysis (Table 4).

To assess the discriminative ability of N/LP ratio for mortality, a ROC curve was produced. The AUC for mortality

Table 3 – Demographic and clinical characteristics of septic AKI patients according to in-hospital mortality.

Characteristics	Survivors (256)	In-hospital mortality (143)	p-value
Age (year)	62.6 ± 15.7	66.6 ± 15.9	0.016
Gender (male) – n (%)	144 (56.3)	85 (59.4)	0.537
Race (Caucasian) – n (%)	245 (95.7)	134 (93.7)	0.381
Obesity – n (%)	77 (28.1)	39 (26.1)	0.554
Co-morbidities – n (%)			
Hypertension	118 (46.1)	64 (44.8)	0.797
Diabetes	57 (22.3)	31 (21.7)	0.892
CVD	16 (6.3)	15 (10.5)	0.129
COPD	18 (7.0)	15 (10.5)	0.229
Cirrhosis	10 (3.9)	7 (4.9)	0.639
Neoplasia	50 (19.5)	46 (32.2)	0.005
Medical admission – n (%)	140 (54.7)	82 (57.3)	0.609
Infection source – n (%)			
Abdominal	106 (41.4)	62 (57.3)	0.705
Respiratory	76 (29.7)	46 (32.2)	0.606
Kidney	35 (13.7)	8 (5.6)	0.013
Skin	20 (7.8)	12 (8.4)	0.838
Others	11 (4.3)	9 (6.3)	0.381
Unknown	8 (3.1)	6 (4.2)	0.577
SAPS II	46.1 ± 15.6	58.1 ± 17.7	<0.001
Baseline SCr (mg/dl)	1.28 ± 0.63	1.25 ± 0.54	0.699
Hemoglobin (g/dl)	10.8 ± 1.9	9.9 ± 2.0	<0.001
Serum albumin (g/dl)	1.94 ± 0.56	1.78 ± 0.6	0.010
NLP ratio	13.66 ± 22.64	31.59 ± 126.8	0.028
Mechanical ventilation – n (%)	182 (71.1)	127 (88.8)	<0.001
Vasopressors – n (%)	173 (67.6)	117 (81.8)	0.002
RRT – n (%)	43 (16.8)	65 (45.5)	<0.001
Fluid balance (l)	3.38 ± 4.6	6.87 ± 5.99	<0.001
LOS in hospital (days)	37.7 ± 36.1	35.1 ± 12.8	0.521
LOS in ICU (days)	9.8 ± 9.8	10.4 ± 10.3	0.609
KDIGO stage 1 – n (%)	70 (27.3)	19 (13.3)	0.001
KDIGO stage 2 – n (%)	79 (30.9)	24 (16.8)	0.002
KDIGO stage 3 – n (%)	107 (41.8)	100 (69.9)	<0.001

prediction in septic-AKI was of 0.565 (95% CI (0.515–0.615), $p=0.034$) (Fig. 2). The optimal cut-off was assessed to be >14, which has a sensitivity of 33.1% and specificity of 79.7% with a positive predictive value of 1.63 and negative predictive value of 0.84, meaning that almost 80% of patients with a NL/P ratio lower than 14 will survive.

Discussion

In this retrospective cohort, we demonstrated that a higher N/LP ratio at ICU admission was independently associated with in-hospital mortality in septic-AKI patients after adjustment to demographic and clinical variables.

The association of this marker with mortality in this setting highlights the role of inflammation in the pathophysiology of septic-AKI.³⁰ The exact mechanisms involved in septic-AKI are unknown, still, this complex process appears to result from the interaction of hemodynamic changes, microcirculatory dysfunction, tubular cell injury, inflammation, coagulation disturbances and adaptive responses to injury.^{12,31}

AKI develops despite an increased renal blood flow in the initial hyperdynamic state of sepsis.³¹ It is theorized that the ultrafiltration of toxins and release of inflammatory cytokines prompts tubular cell injury, endothelial dysfunction,

reduced microcirculatory flow and interstitial inflammatory cell infiltration.^{13,15}

The role of platelet and leukocyte interactions as a critical step in leukocyte recruitment, activation and migration in inflammation has emerged in recent years.^{32,33} Both innate and adaptive immune responses are modulated by the interaction of neutrophils, monocytes, lymphocytes and platelets.^{32,33} There is an intrinsic interaction between inflammation and coagulation pathways in sepsis.³⁴ In the early phases of sepsis platelet/neutrophils complexes are raised, and reduced in severe and complicated sepsis due to peripheral sequestration or sepsis-associated thrombocytopenia.^{35–37}

The systemic inflammation associated with septic-AKI is central in the development of multi-organ failure and long-term outcomes.³⁸ Therefore, the N/LP ratio stands as an indirect and sensitive predictor of inflammation and outcomes in this setting.

The N/L ratio has been described in recent literature as a significant marker for inflammation and a useful predictor of the development of AKI.^{18–21} In patients with septic shock, Riche et al. reported that the N/L ratio correlated with short and long-term mortality.³⁹ Also, Huang et al. demonstrated that the N/L ratio at admission was associated with mortality in patients with severe sepsis and septic shock.⁴⁰ In a study

Table 4 – Univariate and multivariate analysis of factors predictive of mortality in septic-AKI patients.

	Mortality			
	Unadjusted OR (95% CI)	p-value	Adjusted OR (95% CI)	p-value
<i>Demographics</i>				
Age	1.02 (1.00–1.03)	0.016	1.02 (1.00–1.04)	0.004
Male	1.14 (0.75–1.73)	0.537		
Caucasian	0.67 (0.27–1.65)	0.383		
Obesity	0.87 (0.55–1.37)	0.554		
<i>Co-morbidities</i>				
Hypertension	0.95 (0.63–1.43)	0.797		
Diabetes	0.97 (0.59–1.89)	0.892		
CVD	1.76 (0.84–3.67)	0.133		
COPD	1.55 (0.76–3.18)	0.232		
Cirrhosis	1.27 (0.47–3.40)	0.640		
CKD	1.73 (0.91–3.29)	0.095		
Neoplasia	1.40 (1.11–1.78)	0.005	1.11 (0.84–1.47)	0.446
Medical admission	1.11 (0.74–1.69)	0.609		
<i>Infection source</i>				
Abdominal	1.08 (0.72–1.64)	0.705		
Respiratory	1.12 (0.72–1.75)	0.606		
Kidney	0.37 (0.17–0.83)	0.016	0.27 (0.11–0.69)	0.006
Skin	1.08 (0.51–2.28)	0.838		
Others	1.50 (0.61–3.70)	0.383		
<i>At UCI admission</i>				
SAPS II	1.05 (1.03–1.06)	0.000	1.03 (1.01–1.05)	0.001
Baseline SCr	0.93 (0.66–1.32)	0.698		
Hemoglobin	0.79 (0.70–0.88)	0.000	0.79 (0.70–0.90)	0.001
Serum albumin	0.61 (0.42–0.89)	0.011	0.86 (0.56–1.33)	0.507
pH <7.35	1.73 (1.14–2.64)	0.011	1.14 (0.69–1.88)	0.614
NLP ratio	1.01 (1.00–1.02)	0.027	1.01 (1.00–1.02)	0.015
NLP ratio >14	1.79 (1.13–2.83)	0.013	2.14 (1.23–3.71)	0.007
<i>During ICU admission</i>				
Mechanical ventilation	3.23 (1.80–5.80)	0.000	1.28 (0.65–2.53)	0.477
Vasopressors	2.16 (1.31–3.56)	0.003	0.96 (0.53–1.75)	0.903
Fluid balance	1.00 (1.00–1.00)	0.000	1.00 (1.00–1.00)	<0.001
RRT	4.13 (2.59–6.57)	0.000	3.13 (1.76–5.57)	<0.001

by Bu et al., N/L ratio was associated with AKI in patients with sepsis, though there was no association with mortality.⁴¹

The N/LP ratio was developed afterwards by Koo et al. who described its association with AKI and short and long-term mortality after cardiovascular surgery.²² In a recent study, we have also reported the significant correlation between the N/LP ratio and AKI in major abdominal surgery, although the ratio did not correlate significantly with in-hospital mortality.²³

The NL ratio was not predictive of mortality in this cohort; thus, platelet count was incorporated in the ratio to increase its sensitivity in predicting patient outcomes. This is the first study to report the association between the N/LP ratio and mortality in septic-AKI. In the sepsis setting, thrombocytopenia is a marker of critically ill patients and is a recognized risk factor for mortality, therefore, the incorporation of platelets in the ratio increases its sensitivity in predicting patient outcomes.³³

Importantly, the N/LP ratio at admission was an independent predictor of mortality in patients who develop septic-AKI within the first week of admission. More importantly, a NL/P ratio lower than 14 is predictive of patient survival, which further reflects that lower inflammation is associated with lower

mortality in critically ill septic patients. Thus, highlighting the role of the N/LP ratio as a significant marker of systemic inflammatory response at ICU admission.

We address some of the important limitations of this study. Firstly, the results may be compromised by the single-center and retrospective nature of the study with a small cohort of patients. Secondly, we could not assess factors which could influence UO, of which we had hourly measurements. Thirdly, the pre-admission SCr level was unknown in nearly 60% of patients, compelling us to calculate an estimated baseline function using the MDRD equation as recommended, which could overestimate AKI incidence. Fourthly, the power of the ROC curve is light and therefore further studies are necessary before generalization. Finally, we did not address cause-specific mortality.

Despite these limitations, our study has several notable strengths. To the best of our knowledge, this is the first study evaluating the association between the N/LP ratio and in-hospital mortality in septic-AKI patients in an ICU. Also, the high specificity of the NL/P ratio reflects that a low ratio is predictive of patient survival. Additionally, AKI was defined and categorized using both creatinine and UO. Finally, despite the retrospective nature of the study, most of the studied variables




Fig. 2 – AUC of the risk model for the prediction of in-hospital mortality with NL/P ratio in septic-AKI patients.

were registered as part of routine clinical practice on a daily basis and made accessible for analysis.

We highlight the need for further understanding of septic-AKI in order to identify at-risk populations, employ preventive strategies, guaranty an early diagnosis and prompt and adequate treatment, ultimately, improving patient outcomes.

Conclusions

In conclusion, we confirmed that the N/LP ratio at ICU admission was independently associated with in-hospital mortality in septic-AKI patients. The assessment of this ratio is straightforward from a routine blood analysis in ICU patients and can prove useful in identifying patients at risk for mortality.

Ethics approval

Ethics approval and consent to participate.

This study was approved by the Ethical Committee in agreement with institutional guidelines. Due to the retrospective and non-interventional nature of the study, informed consent was waived by the Ethical Committee.

Funding

There was no funding for this study.

Authors' contributions

The authors participated as follows: JG and JAF drafted the article, SJ and JG revised the article, JAL revised the article and approved the final version to be submitted for publication.

Conflict of interest

There is no conflict of interest. The results presented in this paper have not been published previously in whole or part.

Consent for publication

The authors give their consent for publication.

Availability of data and material

All datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Acknowledgements

The authors acknowledge the remaining doctors in the investigation team at the Division of Nephrology and Renal Transplantation of CHULN for the collection of data.

REFERENCES

1. Kellum JA, Prowle JR. Paradigms of acute kidney injury in the intensive care setting. *Nat Rev Nephrol.* 2018;14:217–30.
2. Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med.* 2015;41:1411–23.
3. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. *Clin J Am Soc Nephrol.* 2007;2:431–9.
4. Bouchard J, Acharya A, Cerda J, Maccariello ER, Madarasu RC, Tolwani AJ, et al. A prospective international multicenter study of AKI in the intensive care unit. *Clin J Am Soc Nephrol.* 2015;10:1324–31.
5. Nguyen HB, Smith D. Sepsis in the 21st century: recent definitions and therapeutic advances. *Am J Emerg Med.* 2007;25:564–71.
6. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. *Virulence.* 2013;5:4–11.
7. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA.* 2005;294:813–8.
8. Chertow G, Burdick E, Honour M, Bonventre J, Bates D. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *J Am Soc Nephrol.* 2005;16:3365–70.
9. Hoste EA, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, et al. Global epidemiology and outcomes of acute kidney injury. *Nat Rev Nephrol.* 2018;14:607–25.
10. Wald R, Quinn RR, Adhikari NK, Burns KE, Friedrich JO, Garg AX, et al. Risk of chronic dialysis and death following acute kidney injury. *Am J Med.* 2012;125:585–93.
11. Zarjou A, Agarwal A. Sepsis and acute kidney injury. *J Am Soc Nephrol.* 2011;22:999–1006.
12. Prowle JR, Bellomo R. Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic alterations in the renal circulation. *Semin Nephrol.* 2015;35:64–74.

13. Post EH, Kellum JA, Bellomo R, Vincent J-L. Renal perfusion in sepsis: from macro- to microcirculation. *Kidney Int.* 2017;91:45-6.
14. Ma S, Evans RG, Iguchi N, Tare M, Parkington HC, Bellomo R, et al. Sepsis-induced acute kidney injury: a disease of the microcirculation. *Microcirculation.* 2019;26:e12483.
15. Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. *Shock.* 2014;41:3-11.
16. Rabb H, Griffin MD, McKay DB, Swaminathan S, Pickkers P, Rosner MH, et al. Inflammation in AKI: current understanding, key questions, and knowledge gaps. *J Am Soc Nephrol.* 2016;27:371-9.
17. Mårtensson J, Bellomo R. Pathophysiology of septic acute kidney injury. *Contrib Nephrol.* 2016;187:36-46.
18. Abu Alfeilat M, Slotki I, Shavit L. Single emergency room measurement of neutrophil/lymphocyte ratio for early detection of acute kidney injury (AKI). *Intern Emerg Med.* 2017, <http://dx.doi.org/10.1007/s11739-017-1715-8>.
19. Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. Can neutrophil-lymphocyte ratio be independent risk factor for predicting acute kidney injury in patients with severe sepsis? *Ren Fail.* 2015;37:225-9.
20. Yuan Y, Qiu H, Hu X, Luo T, Gao X, Zhao X, et al. Predictive value of inflammatory factors on contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention. *Clin Cardiol.* 2017;40:719-25.
21. Kim WH, Park JY, Ok SH, Shin IW, Sohn JT. Association between the neutrophil/lymphocyte ratio and acute kidney injury after cardiovascular surgery: a retrospective observational study. *Medicine (Baltimore).* 2015;94:e1867.
22. Koo CH, Eun Jung D, Park YS, Bae J, Cho YJ, Kim WH, et al. Neutrophil, lymphocyte, and platelet counts and acute kidney injury after cardiovascular surgery. *J Cardiothorac Vasc Anesth.* 2017;24. pii:S1053-0770(17)30715-2.
23. Gameiro J, Fonseca JA, Dias JM, Milho J, Rosa R, Jorge S, et al. Neutrophil, lymphocyte and platelet ratio as a predictor of postoperative acute kidney injury in major abdominal surgery. *BMC Nephrol.* 2018;19:320.
24. Pereira M, Rodrigues N, Godinho I, Gameiro J, Neves M, Gouveia J, et al. Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the 'Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease' (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications. *Clin Kidney J.* 2016;1-9.
25. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA.* 1993;270:2957-63.
26. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int.* 2012;2:S1-138.
27. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA.* 2016;315:801-10.
28. ADA. Standards of medical care in diabetes—2009. *Diabetes Care.* 2009;32 Suppl. 1:S13-61.
29. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA.* 2003;289:2560-72.
30. Ostermann M, Liu K. Pathophysiology of AKI. *Best Pract Res Clin Anaesthesiol.* 2017;31:305-14.
31. Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. *Curr Opin Crit Care.* 2014;20:588-95.
32. Li Z, Yang F, Dunn S, Gross AK, Smyth SS. Platelets as immune mediators: their role in host defense responses and sepsis. *Thromb Res.* 2011;127:184-8.
33. Dewitte A, Lepreux S, Villeneuve J, Bae J, Cho YJ, Kim WH, et al. Blood platelets and sepsis pathophysiology: a new therapeutic prospect in critical ill patients? *Ann Intensive Care.* 2018;8:32.
34. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. *Nat Rev Immunol.* 2013;13:34-45.
35. Russwurm S, Vickers J, Meier-Hellmann A, Spangenberg P, Bredle D, Reinhart K, et al. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. *Shock.* 2002;17:263-8.
36. Ioannou A, Kannan L, Tsokos GC. Platelets, complement and tissue inflammation. *Autoimmunity.* 2013;46:1-5.
37. Levi M, van der Poll T. Coagulation and sepsis. *Thromb Res.* 2017;149:38-44.
38. Doi K, Rabb H. Impact of acute kidney injury on distant organ function: recent findings and potential therapeutic targets. *Kidney Int.* 2016;89:555-64.
39. Riche F, Gayat E, Barthelemy R, Le Dorze M, Mateo J, Payen D. Reversal of neutrophil-to-lymphocyte count ratio in early versus late death from septic shock. *Crit Care.* 2015;19:439.
40. Hwang SY, Shin TG, Jo IJ, Jeon K, Suh GY, Lee TR, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in critically-ill septic patients. *Am J Emerg Med.* 2017;35:234-9.
41. Bu X, Zhang L, Chen P, Wu X. Relation of neutrophil-to-lymphocyte ratio to acute kidney injury in patients with sepsis and septic shock: a retrospective study. *Int Immunopharmacol.* 2019;70:372-7.